Table 1

Patient baseline characteristics

Patient characteristicN = 64
Age, median (range), years 64 (32-91) 
Sex, male/female, n (%) 44 (69)/20 (31) 
Disease type, n (%)  
 FL 38 (59) 
 SLL 11 (17) 
 LPL 9 (14) 
 MZL 6 (9) 
Bulky disease (≥1 lymph node ≥5 cm), n (%) 28 (44) 
Elevated LDH 24 (38) 
Cytopenias, n (%) any grade/n (%) grade ≥3  
 Anemia 41 (64)/3 (5) 
 Thrombocytopenia 36 (56)/2 (3) 
 Neutropenia 7 (11)/2 (3) 
Prior therapies, median (range), n 4 (1-10) 
Prior therapy type, n (%)  
 Rituximab 62 (97) 
 Alkylating agent 58 (91) 
 Anthracycline/anthracenedione 33 (52) 
 Purine analog 27 (42) 
 Bendamustine 17 (27) 
Refractory to last prior therapy, n (%)* 37 (58) 
Patient characteristicN = 64
Age, median (range), years 64 (32-91) 
Sex, male/female, n (%) 44 (69)/20 (31) 
Disease type, n (%)  
 FL 38 (59) 
 SLL 11 (17) 
 LPL 9 (14) 
 MZL 6 (9) 
Bulky disease (≥1 lymph node ≥5 cm), n (%) 28 (44) 
Elevated LDH 24 (38) 
Cytopenias, n (%) any grade/n (%) grade ≥3  
 Anemia 41 (64)/3 (5) 
 Thrombocytopenia 36 (56)/2 (3) 
 Neutropenia 7 (11)/2 (3) 
Prior therapies, median (range), n 4 (1-10) 
Prior therapy type, n (%)  
 Rituximab 62 (97) 
 Alkylating agent 58 (91) 
 Anthracycline/anthracenedione 33 (52) 
 Purine analog 27 (42) 
 Bendamustine 17 (27) 
Refractory to last prior therapy, n (%)* 37 (58) 
*

Lack or response or iNHL progression ≤6 mo from completion of last prior therapy.

Close Modal

or Create an Account

Close Modal
Close Modal